CA2370259A1 - Pyrrolidincarbonylamino cyclic disulfides - Google Patents

Pyrrolidincarbonylamino cyclic disulfides Download PDF

Info

Publication number
CA2370259A1
CA2370259A1 CA002370259A CA2370259A CA2370259A1 CA 2370259 A1 CA2370259 A1 CA 2370259A1 CA 002370259 A CA002370259 A CA 002370259A CA 2370259 A CA2370259 A CA 2370259A CA 2370259 A1 CA2370259 A1 CA 2370259A1
Authority
CA
Canada
Prior art keywords
compound
amino
pharmaceutically acceptable
acceptable salt
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002370259A
Other languages
English (en)
French (fr)
Inventor
Li Chen
Nader Fotouhi
David Young Jackson
Jefferson Wright Tilley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2370259A1 publication Critical patent/CA2370259A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0207Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)4-C(=0), e.g. 'isosters', replacing two amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/06Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00Systems containing at least three condensed rings
    • C07C2603/02Ortho- or ortho- and peri-condensed systems
    • C07C2603/04Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
    • C07C2603/12Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
    • C07C2603/18Fluorenes; Hydrogenated fluorenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002370259A 1999-04-20 2000-04-17 Pyrrolidincarbonylamino cyclic disulfides Abandoned CA2370259A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13021599P 1999-04-20 1999-04-20
US60/130,215 1999-04-20
PCT/EP2000/003459 WO2000063234A2 (en) 1999-04-20 2000-04-17 Pyrrolidincarbonylamino cyclic disulfides as vcam-vla4 antagonists

Publications (1)

Publication Number Publication Date
CA2370259A1 true CA2370259A1 (en) 2000-10-26

Family

ID=22443611

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002370259A Abandoned CA2370259A1 (en) 1999-04-20 2000-04-17 Pyrrolidincarbonylamino cyclic disulfides

Country Status (15)

Country Link
US (1) US6265572B1 (https=)
EP (1) EP1171452B1 (https=)
JP (1) JP2002542256A (https=)
KR (1) KR100636481B1 (https=)
CN (1) CN1167710C (https=)
AR (1) AR023546A1 (https=)
AT (1) ATE337331T1 (https=)
AU (1) AU769294B2 (https=)
BR (1) BR0009838A (https=)
CA (1) CA2370259A1 (https=)
DE (1) DE60030266T2 (https=)
ES (1) ES2269141T3 (https=)
TR (1) TR200103004T2 (https=)
WO (1) WO2000063234A2 (https=)
ZA (1) ZA200108018B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6939855B2 (en) 1997-07-31 2005-09-06 Elan Pharmaceuticals, Inc. Anti-inflammatory compositions and method
CA2598816A1 (en) * 2005-02-28 2006-08-31 Medichem S.A. Process and methods for the preparation of gabapentin and its intermediates
EP2124996A4 (en) 2007-02-20 2010-03-24 Merrimack Pharmaceuticals Inc METHOD FOR TREATING MULTIPLE SCLEROSIS BY ADMINISTERING AN ALPHA FETOPROTEIN COMBINED WITH AN INTEGRINANT AGONIST
CA2721093A1 (en) 2008-04-11 2009-10-15 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
CN102282168A (zh) 2008-11-18 2011-12-14 梅里麦克制药股份有限公司 人血清白蛋白接头以及其结合物
CA2850885A1 (en) 2011-10-17 2013-04-25 Westfaelische Wilhelms-Universitaet Muenster Assessment of pml risk and methods based thereon
US20150202287A1 (en) 2012-08-30 2015-07-23 Merrimack Pharmaceuticals, Inc. Combination therapies comprising anti-erbb3 agents
KR102659859B1 (ko) 2018-10-30 2024-04-25 길리애드 사이언시즈, 인코포레이티드 알파4β7 인테그린의 억제를 위한 화합물
AU2019373242B2 (en) 2018-10-30 2023-07-13 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
EP4541422A3 (en) 2018-10-30 2025-06-25 Gilead Sciences, Inc. Quinoline derivatives as alpha4beta7 integrin inhibitors
CN112969700B (zh) 2018-10-30 2024-08-20 吉利德科学公司 作为α4β7整合素抑制剂的咪唑并吡啶衍生物
KR102908219B1 (ko) 2019-08-14 2026-01-08 길리애드 사이언시즈, 인코포레이티드 알파 4 베타 7 인테그린의 저해용 화합물

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5192746A (en) 1990-07-09 1993-03-09 Tanabe Seiyaku Co., Ltd. Cyclic cell adhesion modulation compounds

Also Published As

Publication number Publication date
BR0009838A (pt) 2002-01-08
EP1171452B1 (en) 2006-08-23
AR023546A1 (es) 2002-09-04
KR20010108517A (ko) 2001-12-07
AU4748200A (en) 2000-11-02
WO2000063234A3 (en) 2001-01-18
US6265572B1 (en) 2001-07-24
EP1171452A2 (en) 2002-01-16
DE60030266T2 (de) 2007-07-19
TR200103004T2 (tr) 2002-01-21
AU769294B2 (en) 2004-01-22
ES2269141T3 (es) 2007-04-01
ATE337331T1 (de) 2006-09-15
DE60030266D1 (de) 2006-10-05
WO2000063234A2 (en) 2000-10-26
ZA200108018B (en) 2003-03-26
CN1347419A (zh) 2002-05-01
CN1167710C (zh) 2004-09-22
JP2002542256A (ja) 2002-12-10
KR100636481B1 (ko) 2006-10-18

Similar Documents

Publication Publication Date Title
KR100615760B1 (ko) 엔-알카노일페닐알라닌 유도체
US6458844B2 (en) Diphenyl carbocyclic thioamide derivatives
RU2266901C2 (ru) 4-пиримидинил-n-ацил-l-фенилаланины и фармацевтическая композиция
US5719296A (en) Pseudopeptide lactam inhibitors of peptide binding to MHC class II proteins
EP0618223A2 (en) Peptides inhibiting interleukin 1-bêta release useful as antiinflammatory agents
LT3626B (en) Compounds containing a fused bicycle ring and processing thereof
KR20050010514A (ko) 고지질혈증의 치료를 위한 티아제핀기를 포함하는 펩티드유도체
SK158196A3 (en) Novel farnesyl transferase inhibitors, their preparation and pharmaceutical compositions containing same
AU769294B2 (en) Pyrrolidincarbonylamino cyclic disulfides
PH26816A (en) Diol-containing renin inhibitors
AU642046B2 (en) N-(2-alkyl-3-mercaptoglutaryl)-amino-diaza cycloalkanone derivatives and their use as collagenase inhibitors
KR20150065718A (ko) 인돌린
MX2015004469A (es) Azaindolinas.
JPH06199820A (ja) 三環及び四環式化合物
MXPA01010543A (en) Pyrrolidincarbonylamino cyclic disulfides
IE870861L (en) Azepine and thiazepine derivatives
MXPA00001743A (es) Derivados de n-alcanoilfenilalanina
MXPA01008376A (en) Thioamide derivatives

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued